Monopar Therapeutics Inc.
MNPR•NASDAQ•Healthcare•Biotechnology

About Monopar Therapeutics

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOChandler Robinson
Founded2014
IPO DateDecember 19, 2019
Employees16
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.monopartx.com
Phone847 388 0349
Address
1000 Skokie Boulevard, Suite 350 Wilmette, Illinois 60091 United States

Corporate Identifiers

CIK0001645469
CUSIP61023L108
ISINUS61023L2079
EIN32-0463781
SIC2834

Leadership Team & Key Executives

Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.
Co-Founder, Chief Executive Officer, President and Director
Dr. Christopher M. Starr Ph.D.
Co-Founder and Independent Executive Chairman of the Board
Andrew J. Cittadine M.B.A.
Chief Operating Officer
Quan Anh Vu
Chief Financial Officer, Principal accounting officer and Principal financial officer
Dr. Patrice P. Rioux M.D., Ph.D.
Acting Chief Medical Officer